Revolution in der Cannabismedizin mit Kalytera Therapeutics - 500 Beiträge pro Seite

[sunny3999]

Kalytera Therapeutics ist mit Prof. Dr. Raphael Mechoulam ist seit über 50 Jahren der Gründervater der Cannabisforschung!

https://kalytera.co/

Prof. Dr. Raphael Mechoulam hat so ziemlich alle Preise abgeräumt und für ihn wurde eigens ein Dokumentarfilm hergestellt "The Scientist".

Kalytera Therapeutics hat sich in die hochprofitable Transplantation von Körperteilen, die Abstoßreaktionen hervorrufen können bei Talent Biotech eingekauft. Die Ergebnisse sind beeindruckend! Cannabis als Cannabidolöl verabreicht reduziert die körpereigenen Abwehrreaktionen.

Kalytera Announces Preliminary Results of a Phase 2a Clinical Study by Talent Biotechs in the Prevention of Graft versus Host Disease
By KalyteraJanuary 18, 2017GvHD, Press Release
https://kalytera.co/news/talent-phase-2a-study-data/

Dazu haben sie eine erfolgreiche Finanzierung von ca. 15 Mio umgesetzt und abgeschlossen (1ste Tranche)
Kalytera Announces Closing of First Tranche of Brokered Private Placement
https://kalytera.co/news/kalytera-announces-closing-of-first…

Ein Top Management ist engagiert worden und finanzkräftige Kapitalgeber sind und stehen auch dem Unternehmen zur Seite!
https://kalytera.co/about/management-team/
https://kalytera.co/about/board-of-directors/

Das interessante dabei sie arbeiten direkt mit Aphria einem führenden lizensierten Cannabishersteller aus Kanada zusammen!

Gary Leong ist Direktor bei Kalytera und Chief Scientific Officer of Aphria Inc
Mr. Leong is the Chief Scientific Officer of Aphria Inc., a Health Canada licensed producer of medical cannabis products. Gary has a personal background in quality assurance, quality control, quality system audits, international and domestic regulatory affairs and product research and development. Gary currently is the president of Neautrical Solutions Inc. located in Surrey, British Columbia. Prior to that, he was the Chief Scientific Officer at Jamieson Laboratories Limited. He began at Jamieson in the year 2000 as the Vice President of Scientific and Technical Affairs. He also held the position of Quality Control Manager at Boehringer Ingelheim Consumer Products: Quest Vitamins and Development Officer at Atomic Energy of Canada: Radiochemical Company. Gary’s educational background began with a Bachelors of Science in Chemistry and has taken him most recently to an MBA in Quality Management from City University of Bellevue Washington. Gary is currently affiliated with The Life Sciences Working Team of Windsor-Essex Economic Development Corporation. In the past, he was a member of the Natural Health Products Directorate Program Advisory Committee and a board member of the Ontario Ginseng Innovation and Research Consortium.

Das Unternehmen hat sich darüberhinaus auf Knochenkrankheiten und deren Heilung spezialisiert:
Development Strategy
https://kalytera.co/about/

Bewertet ist das Unternehmen aktuell mit C$ 56 Mio ! Aktuell mit 79 Mio Aktien im Rahmen der bought deal wird das noch etwas erhöhen

Vergleichbare Unternehmen liegen bei dem 5-10 fachen, GW Pharmaceuticals PLC das Leitunternehmen in der Cannabisforschung liegt gar bei 3 Mrd US $.

Also Viel Luft nach oben, das Fundament steht!

[sunny3999]

Kalytera Therapeutics schließt Akquisition von Talent Biotechs

Kalytera Therapeutics Completes Acquisition of Talent Biotechs

https://globenewswire.com/news-release/2017/02/16/918075/0/e…

[sunny3999]

Hier noch ein Beitrag von Prof. Cr. Raphael Mechoulam

https://kalytera.co/cbd/#prodrugs

[sunny3999]

Medizinisches Marihuana wird in Deutschland im April legal

[sunny3999]

Antwort auf Beitrag Nr.: 54.341.111 von sunny3999 am 16.02.17 20:47:43

Talent hat ausser Nordamerika (US-Kanada) auch die Europa Zulaasung

Hatte ich ganz vergessen, da in Europa gerade ein medizinische Freigabe von Marihuana in mehreren Ländern erfolgt!

Aus der News: https://kalytera.co/news/talent-gvhd-loi/

In May 2015, Moshe Yeshurun, M.D., who also serves as the Head of the Bone Marrow Transplantation Department at the Rabin Medical Center in Israel and the Chief Medical Officer of Talent, published results from a Phase 2a clinical study investigating the use of CBD for the prevention of GvHD, with promising initial results1. Results show, that when administering CBD, there is a significant decrease in the incidence of acute and chronic GvHD following transplantation as compared to historical control patients. Talent is conducting several additional pilot studies in the treatment of GvHD and has obtained four orphan drug designations (“ODD”) for the prevention and treatment of GvHD in the U.S. and Europe.

[sunny3999]

Germany becomes latest country to OK medical marijuana legalization

Das Cannabidol ist auf allen Sendern in USA-Kanada, Nachzügler Deutschland wird zu Beginn Marihuana aus Kanada importieren müssen um dem Bedarf gerecht zu werden.

Aphria sollte bald auch da eine Antwort dazu haben.

Link zum CNN Beitrag zur deutschen Legalisierung:

http://edition.cnn.com/2016/12/29/health/global-marijuana-ca…

[sunny3999]

Kalytera hält am 23 Febr. ein Konferenz Call

https://globenewswire.com/news-release/2017/02/16/918304/0/e…

Kalytera Therapeutics to Announce Phase 2a Clinical Study Results Investigating CBD for the Treatment of Acute Graft versus Host Disease

Kalytera to host conference call and webcast on Thursday, February 23, 2017 at 12:00 PM ET

February 16, 2017 16:30 ET | Source: Kalytera Therapeutics, Inc.
VANCOUVER, British Columbia, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY) (“Kalytera”) will announce the results of a Phase 2a study investigating the safety and efficacy of cannabidiol (“CBD”) for the treatment of acute (Grades 3-4) Graft versus Host Disease (“GvHD”) on Wednesday, February 22, 2017. A conference call and webcast will be held on Thursday, February 23, 2017 at 12:00 PM ET to discuss the study results.

The Phase 2a study was conducted by Talent Biotechs, Ltd. (“Talent”), an Israeli-based company evaluating the use of CBD to prevent and treat GvHD, that has been newly acquired by Kalytera.

GvHD is a multisystem disorder that is a common, life-threatening complication of hematopoietic stem cell transplant (“HCT”) procedures. HCT is a lifesaving procedure for many diseases of the blood and bone marrow including leukemia, Hodgkin and Non-Hodgkin lymphoma, and multiple myeloma. GvHD occurs when the transplanted donor cells attack the patient’s organs, including the skin, gastrointestinal tract, liver, lungs, and eyes. GvHD is associated with acute and chronic illness, infections, disability, reduced quality of life, and death.

The Phase 2a treatment study enrolled ten patients with acute GvHD, including five patients with Grade 3 GvHD and five patients with Grade 4 GvHD. All ten patients were steroid refractory, meaning that they had not responded to previously administered standard of care steroid treatment. Patients were administered daily doses of CBD for up to three months, alongside standard of care therapy.

Conference Call and Webcast Information

Date: Thursday, February 23, 2017
Time: 12:00 PM ET
Conference Call: http://dpregister.com/10101838 (Register to receive dial-in instructions)
Webcast: http://services.choruscall.com/links/kaly170223.html (Allow at least ten minutes to access the site before the webcast begins)
The conference call and webcast will be available for replay on the Kalytera website.

About Kalytera Therapeutics
Kalytera (TSXV: KALY) is pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs, with an initial focus on Graft versus Host Disease (“GvHD”).

Kalytera is focused first on developing a new class of proprietary cannabidiol (“CBD”) therapeutics. CBD is a remarkable compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with natural CBD, including its poor oral bioavailability and short half-life. Kalytera is developing innovative CBD formulations and prodrugs in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera intends to file composition of matter and method of use patents covering its novel inventions, with the goal of limiting future competition.

Website Home: https://kalytera.co/
News and Insights: https://kalytera.co/news/
Investors: https://kalytera.co/investors/

[sunny3999]

Untersuchung Marihuana Einfluß durch Scannen des Gehirns zur besten Medikation & Cannabis Zusammensetzung

http://www.marketwatch.com/video/sectorwatch/this-medical-de…

This medical device scans your brain on marijuana(2:52)
The BrainBot, a brain-scanning technology developed by tech startup PotBotics, enables physicians to pick a marijuana strain that is most suited for their patients' needs.

Und 20 unglaubliche Vorteile durch Cannabis
20 Shocking Medical Cannabis Benefits You Need To Know

[sunny3999]

Antwort auf Beitrag Nr.: 54.344.839 von sunny3999 am 17.02.17 10:34:04

20 unglaubliche Vorteile durch Cannabis

20 Shocking Medical Cannabis Benefits You Need To Know
http://herb.co/2016/07/07/benefits-of-medical-cannabis/

[sunny3999]

Neue Vorteile von medizinischem Marijuana

http://www.medicaldaily.com/medical-cannabis-2016-new-benefi…
Medical Cannabis 2016: New Benefits Of Medicinal Marijuana
Sep 26, 2016 07:08 AM By Mary Pascaline Dharshini

Drug Developed For Alzheimer’s Disease Stimulate The Regrowth Of Teeth

Cancer is the second most common cause of death in the U.S. resulting in at least 584,881 deaths, according to the Centers for Disease Control and Prevention. Recent animal studies show that marijuana extracts can help kill certain cancer cells and even reduce the size of some of them. But, marijuana is still illegal in several states. The number of people who’ve died due to an overdose of marijuana? None.

The National Institute on Drug Abuse describes medical marijuana as “using the whole unprocessed marijuana plant or its basic extracts to treat a disease or symptom.” The Food and Drug Administration has, however, neither approved nor recognized the drug as medicine. So far, 25 states have approved the usage of medical marijuana.

Medical marijuana is available in a variety of forms. It can be smoked, vaporized, consumed as a pill or can be added to brownies, cookies and chocolate bars. Here are some of the benefits of using the drug as medicine.

medical marijuana's benefits
The National Institute on Drug Abuse describes medical marijuana as “using the whole unprocessed marijuana plant or its basic extracts to treat a disease or symptom.”
JUSTIN SULLIVAN/GETTY IMAGES

Studies show that marijuana when used with opiates can be used for pain relief.
Researchers from American Academy of Neurology also found that the drug in the form of pills or sprays can reduce stiffness and muscle spasms in multiple sclerosis.
A 2007 study found that cannabis shows promise in reducing pain caused by damaged nerves like in HIV patients.
A 2012 study found that cannabis is also effective in treating schizophrenia.
Scientists from the University of Buffalo’s Research Institute on Addictions found that marijuana is effective in treating depression.
A 2014 study showed that smoking marijuana helped reduce symptoms in patients with post-traumatic stress disorder.
Researchers from Virginia Commonwealth University found that ingredients in marijuana “play a critical role in controlling spontaneous seizures in epilepsy.”
A 2006 study found that the active ingredient in cannabis, tetrahydrocannabinol, is more effective than mainstream drugs in preventing the enzyme acetylcholinesterase from accelerating the formation of “Alzheimer’s plaques” in the brain. It is also more effective in preventing the formation of protein clumps that can inhibit cognition and memory.
The "munchies," a popular effect of consuming marijuana, have been used to stimulate an appetite in HIV/AIDS patients who have a poor appetite due to their condition and treatment.
Researchers from University of Nottingham found that marijuana shows promise in reducing brain damage after a stroke.

[sunny3999]

Kalytera Therapeutics ist noch nicht überall von Santa Maria umgescrieben

Wer sich zu der gesamten Entwicklung von Santa Maria auf Kalytera einlesen möchte kann das hier im SEDAR machen. Steht alles drin wie, warum, wozu und weshalb!

http://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issu…

Hier im speziellen wird alles detailliert erklärt wie aus Santa Maria Petroleum - Kalytera Therapeutics wird. Santa Maria war nur die Hülle eines börsennotierten Unternehmens.

http://www.sedar.com/CheckCode.do

Die Unternehmensseite von Kalytera Therapeutics ist dann hier:

https://kalytera.co/

[sunny3999]

Am 22 Febr. schon eine Pressemeldung zu den Ergebnissen (rot unterstrichen) 23 Febr. Conf Call. (rot)

Kalytera Therapeutics to Announce Phase 2a Clinical Study Results Investigating CBD for the Treatment of Acute Graft versus Host Disease

Kalytera to host conference call and webcast on Thursday, February 23, 2017 at 12:00 PM ET

Weiterempfehlen
February 16, 2017 16:30 ET | Source: Kalytera Therapeutics, Inc.
VANCOUVER, British Columbia, Feb. 16, 2017 (GLOBE NEWSWIRE) --

Kalytera Therapeutics, Inc. (TSXV:KALY) (“Kalytera”) will announce the results of a Phase 2a study investigating the safety and efficacy of cannabidiol (“CBD”) for the treatment of acute (Grades 3-4) Graft versus Host Disease (“GvHD”) on Wednesday, February 22, 2017.

A conference call and webcast will be held on Thursday, February 23, 2017 at 12:00 PM ET to discuss the study results.

The Phase 2a study was conducted by Talent Biotechs, Ltd. (“Talent”), an Israeli-based company evaluating the use of CBD to prevent and treat GvHD, that has been newly acquired by Kalytera.

GvHD is a multisystem disorder that is a common, life-threatening complication of hematopoietic stem cell transplant (“HCT”) procedures. HCT is a lifesaving procedure for many diseases of the blood and bone marrow including leukemia, Hodgkin and Non-Hodgkin lymphoma, and multiple myeloma. GvHD occurs when the transplanted donor cells attack the patient’s organs, including the skin, gastrointestinal tract, liver, lungs, and eyes. GvHD is associated with acute and chronic illness, infections, disability, reduced quality of life, and death.

The Phase 2a treatment study enrolled ten patients with acute GvHD, including five patients with Grade 3 GvHD and five patients with Grade 4 GvHD. All ten patients were steroid refractory, meaning that they had not responded to previously administered standard of care steroid treatment. Patients were administered daily doses of CBD for up to three months, alongside standard of care therapy.

Conference Call and Webcast Information

Date: Thursday, February 23, 2017
Time: 12:00 PM ET
Conference Call: http://dpregister.com/10101838 (Register to receive dial-in instructions)
Webcast: http://services.choruscall.com/links/kaly170223.html (Allow at least ten minutes to access the site before the webcast begins)
The conference call and webcast will be available for replay on the Kalytera website.

About Kalytera Therapeutics
Kalytera (TSXV: KALY) is pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs, with an initial focus on Graft versus Host Disease (“GvHD”).

Kalytera is focused first on developing a new class of proprietary cannabidiol (“CBD”) therapeutics. CBD is a remarkable compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with natural CBD, including its poor oral bioavailability and short half-life. Kalytera is developing innovative CBD formulations and prodrugs in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera intends to file composition of matter and method of use patents covering its novel inventions, with the goal of limiting future competition.

Website Home: https://kalytera.co/
News and Insights: https://kalytera.co/news/
Investors: https://kalytera.co/investors/
Cautionary Note
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) has in any way passed upon the merits of the proposed Transaction and associated transactions and neither of the foregoing entities has in any way approved or disapproved of the contents of this press release.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Forward-Looking Statement Disclosure
This news release contains “forward-looking information” within the meaning of applicable securities laws, including information relating to the Phase 2a clinical trial. Although Kalytera believes in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because Kalytera can give no assurance that they will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the risks of failure of the results of the Phase 2a clinical trial to be consistent with the preliminary results of such trial, that the Phase 2a clinical trial results are not determinative of or consistent with the results of the results of future Phase 2 or other clinical studies, that the small number of patients in the Phase 2a clinical trial may contribute to the risk that future studies may be inconsistent with the results of the Phase 2a clinical trial, and that clinical trials are subject to a number of other health, safety, efficacy and regulatory risks. The statements in this press release are made as of the date of this release. Kalytera undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Kalytera, Talent, their securities, or their respective financial or operating results (as applicable). Kalytera disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Company Contact
Robert Farrell
President, COO and CFO
Phone: [phone]
Email: [e-mail]

[sunny3999]

Patente, Patente Kalytera Patente!

Auszug aus der Januar News!

The license for this patent was obtained from Mor Research Applications Ltd., the technology transfer company of Clalit Health Services, the largest HMO (Health Maintenance Organization) in Israel.
“We are thrilled to announce the signing of this LOI, which brings us closer to acquiring a late-stage program in GvHD with strong proof-of-concept,” said David Stefansky, Co-Founder of Kalytera and Chairman of the Board of Directors. “There are currently few options to prevent or treat GvHD. We feel incredibly fortunate to be working towards the advancement of this important program.”
“Multiple studies have demonstrated that CBD possesses remarkable therapeutic potential across a broad range of diseases and disorders,” said Andrew Salzman, M.D., Kalytera Chief Executive Officer. “The proposed acquisition of Talent and its late-stage GvHD program significantly advances Kalytera’s mission of becoming a global leader in CBD pharmaceuticals. We are encouraged by Talent’s GvHD data and we are hopeful that Kalytera will be able to rapidly advance the program into placebo-controlled, double blind, randomized studies.”

Summary of Transaction Terms
As consideration for the acquisition of Talent, Kalytera will provide a combination of cash, securities and future contingent payments. Under the terms of the LOI, Kalytera has made a non-refundable payment of USD$1,000,000 to Talent, and, at closing, Kalytera will pay an additional USD$9,000,000 cash and will issue such number of common shares as is equal to 15% of Kalytera’s outstanding common shares prior to closing. Subject to the completion of certain milestones in relation to the development and commercialization GvHD treatments, Kalytera will pay up to USD$20,000,000 in aggregate future contingent payments. Kalytera shall also issue an additional number of common shares as is equal to 2.5% of Kalytera’s outstanding common shares prior to closing of the Transaction, in each case upon the completion of the first Phase 2 clinical study and upon the issuance of the first patent by the USPTO or EU with respect to certain assets of Talent acquired in connection with the Transaction. The vendors of Talent shall also receive additional royalty payments equal to 5% of the aggregate annual net sales of all products covered by patent rights included in the business of Talent.

Read more at http://www.stockhouse.com/companies/bullboard?symbol=quezf&p…

[sunny3999]

Multibillion Hemp Market Talk

[sunny3999]

Chart One World Cannabis Pharmaceuticals Chart = Israelisches Pharmaunternehmen wie Kalytera...

....das könnte demnächst auch mit Kalytera Therapeutics passieren!

[sunny3999]

Kalytera Chart glüht auch schon vor für die anstehende News und Conf Call!

[sunny3999]

Kalytera Therapeutics Offers Alternative To Current Osteoporosis Treatment

http://seekingalpha.com/article/4045322-kalytera-therapeutic…

[sunny3999]

Kalytera Partner Aphria leitet und investiert in Übernahme eines weiteren Pharmaunternehmens durch RTO

http://scythianbio.com/ Neues Pharmaunternehmen zur Gehirnforschung (speziell Concussion)
http://www.kitrinormetals.com/news.php Minenunternehmen nur als Revers Take Over Hülle

Scythian Biosciences Inc is developing a proprietary Cannabinoid (CBD) combination therapy for the prevention and treatment of concussions and traumatic brain injury

TORONTO, ONTARIO–(Marketwired – Feb. 21, 2017) –

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

Kitrinor Metals Inc. (TSX VENTURE:KIT) (the “Company“) is pleased to announce that it has entered into a non-binding letter of intent dated February 17, 2017 (the “Letter of Intent“) with Scythian Biosciences Inc., a private Canadian corporation (“Scythian“), in connection with a proposed reverse take-over of the Company (the “Proposed Transaction“), subject to approval of the TSX Venture Exchange (“TSXV“), to list the shares of the resulting entity (the “Resulting Issuer”) on the TSXV. The Resulting Issuer will operate as a life sciences issuer continuing the business of Scythian. Aphria Inc. (TSX VENTURE:APH)(OTCQB:APHQF) is expected to be a lead investor in the Offering as defined below.

Proposed Transaction

The Letter of Intent provides that the Company and Scythian will negotiate and enter into a definitive agreement in respect of the Proposed Transaction on or before March 10, 2017 (the “Definitive Agreement“).

Pursuant to the terms of the Letter of Intent, completion of the Proposed Transaction will be subject to a number of conditions, including completion of an Offering (described below), shareholder approval, if required, completion or waiver of sponsorship, receipt of all required regulatory approvals, including the approval of the TSXV, completion of satisfactory due diligence reviews, satisfaction of the initial listing requirements of the TSXV and all requirements under the policies of the TSXV relating to the completion of the Proposed Transaction, and execution of the Definitive Agreement.

The Company and Scythian will complete the Proposed Transaction by way of a three-cornered amalgamation whereby a wholly-owned subsidiary of the Company will amalgamate with Scythian to form a wholly-owned subsidiary of the Resulting Issuer. The Proposed Transaction is an arm’s length transaction.

Prior to or contemporaneously with the completion of the Proposed Transaction, Scythian will complete a consolidation of its issued and outstanding common shares on a 4 for 1 basis.

The anticipated completion date for the Proposed Transaction is May 31, 2017.

A filing statement or management information circular, as applicable, will be prepared and filed in accordance with the policies of the TSXV.

Concurrent Financing

As a condition to the completion of the Proposed Transaction, Scythian will complete a brokered subscription receipt financing, through a syndicate of agents led by Clarus Securities Inc. and including Haywood Securities Inc. and Canaccord Genuity Corp. (the “Agents“), for aggregate gross proceeds of up to $10,000,000 through the issuance of up to 25,000,000 subscription receipts (“Subscription Receipts“) at a price of $0.40 per Subscription Receipt (the “Offering“), subject to the rules of, and approval by, the TSXV. Upon satisfaction of the escrow release conditions, including all conditions precedent to the Proposed Transaction being satisfied, each Subscription Receipt will automatically convert without any further action on the part of the holder into one (1) common share of the Resulting Issuer. Should the escrow release conditions not be satisfied, the Subscription Receipts will be cancelled and all proceeds from the sale of Subscription Receipts will be returned to subscribers without interest.

As compensation for the services provided in connection with the Offering, the Agents will receive a cash commission equal to 7% of the gross proceeds raised in connection with the Offering and broker warrants equal to 7% of the Resulting Issuer shares.

Upon completion of the Proposed Transaction, the proceeds of the Offering will be used to further develop the business of the Resulting Issuer and for general working capital purposes.

Sponsorship

Sponsorship of the Proposed Transaction may be required by the TSXV unless an exemption or waiver from this requirement can be obtained in accordance with the policies of the TSXV. The Company intends to apply for a waiver of the sponsorship requirement. There is no assurance that a waiver from this requirement can or will be obtained.

About Scythian Biosciences Inc

Scythian is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury (“TBI“) with its proprietary Cannabinoid (“CBD”) combination.

Scythian’s mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen. The University of Miami believes that Scythian’s scientific approach shows significant promise and differs from previous approaches to treat this growing problem. The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian’s clinical studies to be undertaken at their world-class facilities.

Gillian A. Hotz, PhD, is leading Scythian’s program at the University of Miami. Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation. She has extensive experience in neurocognitive testing. Dr. Hotz has been the co-director of University of Miami Miller School of Medicine’s Concussion Program since 1995.

Scythian is also endorsed by the NFL Alumni Association and the World Boxing Association on its mission.

About Kitrinor Metals Inc.

Kitrinor is a junior mining exploration company engaged in the acquisition, exploration and development of mineral resource properties in Canada. The Company’s activities are currently focused on the exploration and development of the Culroc Property located in the Township of Sothman, Ontario.

Additional Information

The common shares of the Company are currently halted from trading pending completion of the Proposed Transaction.

A comprehensive press release with further particulars relating to the Proposed Transaction, financial particulars and descriptions of the proposed board of directors and management of the Resulting Issuer will follow in accordance with the policies of the TSXV.

All information contained in this press release with respect to the Company and Scythian was supplied by the parties respectively, for inclusion herein, and each party and its directors and officers have relied on the other party for any information concerning the other party.

[sunny3999]

Kalytera's neues Logo, Homepage mit Partner Aphria

Link to Aphria Partner - Kalytera Therapeutics "new" Logo & …

Link of Aphria's Map of Operations, Partner and Brands

Link: By the way Kalythera will release a news today and wil…

Dieses Bild ist nicht SSL-verschlüsselt: [url]http://img5.fotos-hochladen.net/uploads/aphrianewkalymtpr37xnoh.jpg

[/url]

[sunny3999]

Kalytera's Prodrug Milliarden Markt laut neuer Hompage!

https://kalytera.co/programs/prodrugs/

Prodrugs

K-1012

Therapeutic goal and molecular design K-1012 is a novel prodrug invented by Kalytera Therapeutics, intended for the treatment of Adult respiratory distress syndrome (ARDS). Designed as a bi-phosphate derivative of cannabidiol (CBD), K-1012 will be administrated intratracheally via a novel formulation expected to increase the bioavailability of CBD, known for its immunosuppressive and anti-inflammatory properties.

Intended mechanism of action Direct exposure to the lungs is a prerequisite in ARDS therapy, thus we have developed an aerosolized formulation. In contrast with CBD, K-1012 is soluble in aqueous solutions, allowing the development of an isotonic solution for an aerosolized formulation. Due to the negative charge of the phosphate groups, K-1012 is predicted to be entrapped in the lumen until being cleaved. Given the increased levels of lung alkaline phosphatase (ALP) in lung lavage as a result of pulmonary damage, we predict ALP will liberate bioactive CBD in ARDS disease models. Progressive ARDS is closely linked to activation of inflammation. The benefits of CBD are expected to be augmented via specific targeting of K-1012 by the phosphate groups, inducing prevention of long-term effects of ARDS.

Current pharmacology studies In vivo efficacy studies in rodent models of E. coli LPS induced ARDS have been utilized to determine appropriate dosing and exposure time. These data will provide a rationale for assessment of K-1012 in a model testing efficacy via systemic exposure. We expect to carry out detailed ADME/PK analysis in rats as well as a non-clinical safety assessment of K-1012 in rats and dogs that will include safety pharmacology and toxicology studies, to complete IND enabling studies.

Unmet need To date, no effective therapy exists for ARDS, thus there remains an urgent need for a new first line therapeutic to improve the survival of patients suffering with ARDS. The development of K-1012 will provide the first pharmacological treatment for patients with ARDS.



K-1022

Therapeutic goal K-1022 is a novel prodrug invented by Kalytera Therapeutics, intended for the treatment of Ulcerative Colitis (UC), a chronic condition characterized by inflammation of the colonic mucosa extending from the rectum proximally to varying portions of the large intestine. The increase in pro-inflammatory factors promotes inflammation and facilitates damage to intestinal tissues. Understanding the pathophysiology of colitis has provided us an opportunity to identify new targets for this disease. The active parent compound of K-1022, CBD, is known for its immunosuppressive and anti-inflammatory properties.

Molecular design and intended mechanism of action Designed as a bi-sulfate derivative of cannabidiol (CBD) with a novel formulation, K-1022 will be administered orally to maximize the anti-inflammatory effect of CBD. The rationale for constructing a sulfate-derivitized prodrug of CBD (K-1022) lies in the augmented delivery to the colon, where K-1022 will be converted to the active compound via the activity of colon-specific sulfatases. In contrast to CBD, the disulfated derivative is water soluble, enhancing the probability of developing a successful oral formulation of K-1022. Given the safety profile and anti-inflammatory properties of CBD, it is expected that K-1022 may serve as a potent and tolerated treatment for UC.

Current pharmacology studies In vivo efficacy studies have been used to determine suitable dosing and exposure time. These data will provide a rationale for assessment of K-1022 in a model testing efficacy via systemic exposure. In the near future, we will perform detailed ADME/PK analysis in rats, as well as non-clinical safety assessment of K-1022 in rats and dogs that will include safety pharmacology and toxicology studies, to complete IND enabling studies.

Unmet need Presently, there are no efficacious treatments for UC, that effectively manage inflammation associated with this disease. No therapeutic on the market today targets severe UC patients, who have a poor prognosis and require hospitalization. Therefore, the development of K-1022 will provide a first line treatment for patients afflicted with severe UC.



K-1032

Therapeutic goal K-1032 is a novel prodrug invented by Kalytera Therapeutics, intended for the treatment of the chronic skin diseases Atopic dermatitis (AD) and Acne Vulgaris. K-1032 is the L-valine-ester derivative of CBD. AD is a chronic disease of the skin caused by skin barrier dysfunction, which together with environmental factors and immune system variability, leads to eczematous and itchy lesions at the flexural folds. Acne is a chronic inflammatory disease of the sebaceous-pilosebaceous unit. Acne vulgaris is the most common skin disease, affecting 45 million people in the USA; nearly 80 percent of adolescents present with acne. Progressive AD and acne are closely linked to activation of inflammation. CBD, is known for its immunosuppressive and anti-inflammatory properties, which has been demonstrated in rodent models of arthritis via transdermal application. Thus, we elect K-1032 as novel candidate for the treatment of AD and acne, which we anticipate to suppress the inflammation present in both chronic skin diseases.

Molecular design and intended mechanism of action K-1032 was selected as a relevant prodrug since substantial evidence has been provided to support the assertion that the biotransformation of drugs, including CBD, occurs in human skin, and that this biotransformation may impair efficacy. Esterases have particularly high activity in the epidermis and hair follicles. These intracellular esterases are important for metabolism and/or pro-drug activation. Nonspecific esterase activity has been demonstrated in human skin and cultured skin cells preventing the drugs to be delivered to the systemic circulation so that biotransformation will occur within the skin. Our assumption is that K-1032 will be captured in the skin, due to the valine moiety, and rapidly cleaved by esterases to yield the active CBD. We are currently developing a formulation for K-1032 to be administered topically.

Current pharmacology studies In vivo efficacy studies in a rodent model of acne have been used to determine suitable dosing and exposure time. These data will provide a rationale for assessment of K-1032 in a model testing efficacy via systemic exposure. We intend to undergo detailed ADME/PK analysis of K-1032 in pigs, as well as non-clinical safety assessment of K-1032 in rats and dogs that will include safety pharmacology and toxicology studies, to complete IND enabling studies.

Unmet need AD is one of the most common chronic inflammatory skin diseases that affect both children and adults with an increased prevalence of 2–3 fold during the last century, particularly in industrialized countries. Despite its increased prevalence worldwide, no specific therapies for AD exist that provide long-term remission for patients with moderate to severe AD. Despite the advantage of topical products and systemic drugs that have being applied to treat acne, they possess side effects. Therefore, there remains an unmet need for an effective treatment for improvement the outcome of acne and AD.



K-1042

Therapeutic goal K-1042 is a novel prodrug invented by Kalytera Therapeutics, intended for the treatment of Acute renal failure (ARF). Designed as a boronic acid derivative of cannabidiol (CBD), K-1042 is being developed to improve the long-term outcome of ARF patients. ARF is a syndrome characterized by rapid loss of kidney function, specifically the glomerular filtration rate, measured by increases in serum creatinine and limited or lack of urine output. ARF is a common complication of acute illness, affecting more than 35% of critically ill patients. Despite advances in treatment and prevention, ARF continues to be associated with high rates of mortality and morbidity, particularly for patients admitted to the intensive care unit (ICU), where mortality rates can exceed 50%. Various types of injury lead to ARF. Common to all these injuries is an inflammatory response due to the kidney insult. The active parent compound of K-1042, CBD, is known for its immunosuppressive and anti-inflammatory properties. Thus, we elect K-1042 as novel candidate for the treatment of ARF, which we anticipate to suppress the inflammation present in ARF patients and prevent long-term kidney failure.

Molecular design and intended mechanism of action We expect the prodrug boronate moiety to undergo kidney-specific cleavage due to increased local levels of hydrogen peroxide produced in ARF patients. Our novel formulation will be administered intravenously (IV) to hospitalized patients, in order to avoid first-pass metabolism of CBD and improve the pharmacokinetic (PK) profile. The combination of direct targeting to the kidney along with the novel formulation design are expected to increase the efficacy of CBD and prevent the long-term consequences ARF.

Current pharmacology studies In vivo efficacy studies in a rodent models of renal ischemia, induced by sepsis or reperfusion injury, have been used to determine suitable dosing and exposure time. These data will provide a rationale for assessment of K-1042 in a model testing efficacy via systemic exposure. Additionally, we intend to undertake detailed pharmacokinetic studies in rats. Data obtained from these studies will be utilized in the future to design clinical PBPK/PD-based human models to inform the design of clinical PK studies. Non-clinical safety assessment of K-1042 will include safety pharmacology and toxicology studies. These investigations will include separate studies that permit full toxicokinetic (TK) characterization of K-1042. The toxicology of K-1042 will be evaluated in rats and dogs, 2 pharmacologically-relevant species, given IV, the intended route of administration in humans.

Unmet need The standard of care for the treatment of ARF is renal replacement therapy, which is supportive but not curative. To date, there is no drug treatment for acute renal failure. Thus, an urgent need remains to develop an effective treatment for ARF. Therefore, the development of K-1042 will provide the first pharmacological treatment for patients suffering from ARF.



K-1052

Therapeutic goal K-1052 is a novel cannabidiol (CBD)-based pharmaceutical composition invented by Kalytera Therapeutics, intended for the treatment Traumatic brain injury (TBI). K-1052 is a di-GW274150 ((S)-2-amino-(1-iminoethylamino)-5-thioheptanoic acid) derivative of CBD. TBI is a highly complex multi-factorial disorder, which involves primary and secondary injury cascades that underlie delayed neuronal dysfunction and death. Following head injury, TBI is a consequence of neuroinflammation caused by an increase in reactive oxygen species (ROS) production and a concomitant increase in levels of inflammatory cytokines.

Molecular design and intended mechanism of action K-1052 consists of two pharmacologically active components, that are coupled together into a single prodrug molecule. The first one, CBD, is known for its neuroprotective role and is therefore expected to control TBI-associated neuroinflammation. The second component, (S)-2-amino-(1-iminoethylamino)-5-thioheptanoic acid, is a specific inducible Nitric Oxide synthase (iNOS) inhibitor that has been tested in phase III human clinical trials for other indications. K-1052 was selected as a relevant prodrug since iNOS-produced nitric oxide (NO) was shown to mediate blood-brain barrier (BBB) damage, and consequently drive the formation of post-traumatic brain edema. We predict that a combination of these two neuroprotective compounds will result in an extremely powerful anti-inflammatory treatment.

Current pharmacology studies In vivo efficacy studies in a rodent models of TBI, have been used to determine suitable dosing and exposure time. These data will provide a rationale for assessment of K-1052 in a model testing efficacy via systemic exposure. Additionally, we intend to undertake detailed pharmacokinetic studies in rats. Data obtained from these studies will be utilized in the future to design clinical PBPK/PD-based human models to inform the design of clinical PK studies. Non-clinical safety assessment of K-1052 will include safety pharmacology and toxicology studies. These investigations will include separate studies that permit full toxicokinetic (TK) characterization of K-1052. The toxicology of K-1052 will be evaluated in rats and dogs, 2 pharmacologically-relevant species, given IV, the intended route of administration in humans.

Unmet need Currently, there is no efficacious therapeutic or intervention utilized by physicians in daily clinical practice for TBI patients. Hence the urgent requirement for an effective therapy for TBI.



K-1062

Therapeutic goal K-1062 is a novel cannabidiol (CBD)-based pharmaceutical composition invented by Kalytera Therapeutics, intended for the treatment Congestive Heart Failure (CHF). K-1062 is a di-nitrate-derivative of CBD. CHF is characterized by a rousing cardiac injury that triggers a cascade of neurohormonal responses, commonly associated with poor quality of life, frequent hospital admissions, and poor survival affecting approximately 26 million people worldwide (Arroll B et al., 2010), (Verschure DO et al., 2016).

Molecular design and intended mechanism of action K-1062 consists of two pharmacologically active components, that are coupled together into a single prodrug molecule. The first one, CBD, is known for its anti-inflammatory role and is therefore expected to control CHF-associated inflammation. The second component, is organic nitrates (ONs) which have a direct relaxant effect on vascular smooth muscles and the dilation of coronary vessels improves oxygen supply to the myocardium (Torfgard, K.E, 1994). We predict that a combination of these two compounds will result in useful treatment for patients with CHF.

Current pharmacology studies In vivo efficacy studies in a rodent models of CHF, have been used to determine suitable dosing and exposure time. These data will provide a rationale for assessment of K-1062 in a model testing efficacy via systemic exposure. Additionally, we intend to undertake detailed pharmacokinetic studies in rats. Data obtained from these studies will be utilized in the future to design clinical PBPK/PD-based human models to inform the design of clinical PK studies. Non-clinical safety assessment of K-1062 will include safety pharmacology and toxicology studies. These investigations will include separate studies that permit full toxicokinetic (TK) characterization of K-1062. The toxicology of K-1062 will be evaluated in rats and dogs, 2 pharmacologically-relevant species, administered sublingually, the intended route of administration in humans. The advantage of sublingual administration for CHF is direct absorption into systemic circulation, thus avoiding degradation in the gastrointestinal (GI) tract and first pass effect.

Unmet need Although conventional drugs known for treating CHF improved survival, the prognosis of CHF remains poor. Thus, there remains a need to develop new therapeutics to treat CHF.

[sunny3999]

Kalytera gibt viel versprechende Resultate einer GvHD Study bekannt

https://globenewswire.com/news-release/2017/02/22/926419/0/en/Kalytera-Therapeutics-Announces-Encouraging-Results-of-a-Phase-2a-Clinical-Study-for-the-Treatment-of-Acute-Graft-versus-Host-Disease.html

Read more at http://www.stockhouse.com/companies/bullboard?symbol=quezf&p…

[sunny3999]

Kalytera Therapeutics Webcast um 18 Uhr MEZ

Link:http://services.choruscall.com/links/kaly170223.htmlLink: Registration for webcast -
Is this the conference for which you would like to register?
Conference Details
Hosting Company: Kalytera Therapeutics, Inc.
Conference Title: Conference Call to Discuss Phase 2a Clinical Study Results Investigating CBD for the Treatment of Acute GvHD

Conductor: Andrew L. Salzman, M.D., Chief Executive Officer
Scheduled Date: Thursday, February 23, 2017
Scheduled Time: 12:00 PM
Time Zone: (GMT -5:00) Eastern Time (US & Canada)
Your Local Time: 6:00 PM
Estimated Duration: 1 hour
Notes: To view the webcast for this conference, please click on the following

Date: Thursday, February 23, 2017
Time: 12:00 PM ET
Conference Call: http://dpregister.com/10101838 (Register to receive dial-in instructions)
Webcast: http://services.choruscall.com/links/kaly170223.html (Allow at least ten minutes to access the site before the webcast begins)

[sunny3999]

Kurzzusammenfassung des gestrigen Conf. Calls aus dem Stockhouse

Meine Meinung: Laut Management soll es 1 Jahr bis zum Start der Phase 2b benötigen und dann noch 18 Monate bis weltweit alle Untersuchungen mit Ergebnissen aufwarten. Ich kann mir nicht vorstellen das ein Top Management soviel Geld investiert in ein Unternehmen ohne das da mehr dahinter ist.

I listened to the conference call. As with any drug company this will be a long term that may or may not provide dividends down the road.

Key points that I took away:
studies have been "positive" so far;
next trial period will not commence until Jan 2018 (maybe a bit sooner)
could last 18 months which puts them to june/ july 2019
there are competitors, so urgency to proceed in timely fashion
Current cash in bank $4 million
Current burn rate is $150k to $200k per month
at current burn rate they have one year of operating cash in bank;
burn rate will increase towards end of year as they get closer to launching new study; and
they will have to raise additional cash before year end
might see share price drift lower before it goes higher
There will be another bought deal later in the year to raise additional cash (IMO).
Curious to know if people think its best to jump in now or later in the year?
Read more at http://www.stockhouse.com/companies/bullboard?symbol=v.smq&p…

[sunny3999]

Aphria schließt Finanzierung von $ 57,5 Mio ab und kauft sich weiter bei Kalytera ein!

Aphria Announces Closing of Bought Deal Financing

Nachrichtenquelle: Marketwired | 24.02.2017, 15:20 | 72 | 0 | 0 LEAMINGTON, ONTARIO--(Marketwired - Feb. 24, 2017) - NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Aphria Inc. ("Aphria" or the "Company") (TSX VENTURE:APH)(OTCQB:APHQF) is pleased to announce it has closed its short form prospectus offering, on a bought deal basis, including the exercise in full of the underwriters' over-allotment option. A total of 11,500,000 common shares (the "Shares") of the Company were sold at a price of $5.00 per Share, for aggregate gross proceeds of $57,500,000 (the "Offering"). The Offering was underwritten by a syndicate of underwriters led by Clarus Securities Inc. and included Cormark Securities Inc., Canaccord Genuity Corp., Haywood Securities Inc. and PI Financial Corp (collectively, the "Underwriters"). The net proceeds of the Offering are expected to be used in connection with the Company's ongoing Part IV Expansion project and for strategic investments. It is currently anticipated that Part IV Expansion is expected to commence during the Company's third quarter. Until spent by the Company, the net proceeds of the Offering will be held as cash balances in the Company's bank account or invested at the discretion of the Company's Board of Directors. The Shares were offered for sale in each of the provinces of Canada, other than the Province of Quebec, by short form prospectus, and in those jurisdictions outside of Canada and the United States which were agreed to by the Company and the Underwriters, where the Shares were issued on a private placement basis, exempt from any prospectus, registration or other similar requirements. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities of Aphria Inc. in the United States, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities offered have not been and will not be registered under the U.S. Securities Act or any U.S. state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or unless an exemption from such registration is available. Additional investment in Kalytera Therapeutics, Inc. The Company also announces that, on February 7, 2017, the Company acquired 2,222,000 common shares of Kalytera Therapeutics, Inc. ("Kalytera") at a price of $0.45 per share, for an aggregate purchase price of $999,900. This transaction was part of Kalytera's private placement announced on January 23, 2017. Further, on February 21, 2017, the Company purchased an additional 1,450,000 common shares of Kalytera on the secondary market. As of today's date, the Company owns 6,172,000 common shares in Kalytera, representing approximately 4.8% of their issued and outstanding shares. About Aphria Aphria Inc., one of Canada's lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. We are the first public licenced producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to internal expectations, the use of proceeds of the Offering and the intended expansion of the Company's facility and the anticipated timing with respect to such expansion. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of Aphria to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Neither the TSX Venture Exchange (the "Exchange") nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release. Aphria Inc. Vic Neufeld President & CEO 1-844-427-4742

Aphria Announces Closing of Bought Deal Financing | wallstreet-online.de - Vollständiger Artikel unter:
http://www.wallstreet-online.de/nachricht/9348958-aphria-ann…

[sunny3999]

Hinter dem Aphria invest in Kalytera steckt etwas mehr...

http://www.stockhouse.com/companies/bullboard?symbol=v.smq&p…
Aphria news stated following
Additional investment in Kalytera Therapeutics Inc.

The company also announces that, on Feb. 7, 2017, the company acquired 2,222,000 common shares of Kalytera Therapeutics at a price of 45 cents per share for an aggregate purchase price of $999,900. This transaction was part of Kalytera's private placement announced on Jan. 23, 2017. Further, on Feb. 21, 2017, the company purchased an additional 1.45 million common shares of Kalytera on the secondary market. As of today's date, the company owns 6,172,000 common shares in Kalytera, representing approximately 4.8 per cent of its issued and outstanding shares.

I think there is more and always the same Management Team
sunny3999 wrote: There is more behind: Tisbury Pharmaceuticals the whole team is/was already at Tisbury Ph.

and more:
SALZMAN CAPITAL VENTURES


and more: Radikal RX

and more:
Quitsa Pharmaceuticals


and more: Respirometics (RSPX)

and more:
Menemsha Pharmaceuticals

[sunny3999]

Aphria will invest more into Kalytera as they are Top Notch at Management level and there study to come.

...they believe in next round of financing they will buy in as well as this will bring huge payback....Vic said! RE:RE:RE:Aphria Storey - Today Read more at http://www.stockhouse.com/companies/bullboard?symbol=quezf&p…

Link zum Leafcast:
https://soundcloud.com/leafcast/medical-cannabis-licensed-pr…

[sunny3999]

Kalytera beantragt 5 Mio Forschungs- und Entwicklungsgelder von der israelischen Innovationsbehörde IIA

https://globenewswire.com/news-release/2017/04/17/961274/0/e…



Kalytera Applies for $5 Million R&D Grant from IIA


Print
April 17, 2017 08:30 ET | Source: Kalytera Therapeutics, Inc.
VANCOUVER, British Columbia, April 17, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSXV:KALY), a clinical stage biopharmaceutical company developing next generation cannabinoid-derived therapeutics, today announced it has applied for a $5 million grant from the Israel Innovation Authority (“IIA”) to fund development of its portfolio of novel cannabidiol (“CBD”) prodrugs.

IIA, formerly known as the Office of the Chief Scientist of the Ministry of Economy (or “MATIMOP”), which is responsible for the country’s innovation policy, is an independent and impartial public entity that operates for the benefit of the Israeli innovation ecosystem and Israeli economy as a whole.

Many of the world’s top-tier biopharmaceutical scientists, CROs and expert research facilities specializing in cannabis are located in Israel, including several of Kalytera’s senior scientific staff and advisors. Accordingly, Israel is widely acknowledged as the global center for FDA and EMEA-compliant pharmaceutical research on cannabis and its molecular constituents such as CBD. It is the ideal location for Kalytera, whose business model is to develop cannabidiol-derived, FDA-approved medicines for global distribution.

Kalytera has applied for the grant to support further development of its portfolio of novel cannabidiol prodrugs, all of which were invented by Kalytera. Kalytera’s CBD prodrugs are listed below:

K-1012, indicated for Acute Respiratory Distress Syndrome (“ARDS”), with an estimated 280,000 patients just in the US and a $700 million addressable market.

K-1022, indicated for Ulcerative Colitis (also known as Irritable Bowel Syndrome, or “IBS”), with an estimated 800,000 US patients and a $10 billion addressable market.

K-1032, indicated for Acne Vulgaris, with an estimated 45 million patients in the US and the five other major markets with a $4 billion addressable market.

K-1052, being studied as an Inducible Nitric Oxide Synthase Inhibitor, indicated for Sepsis Associated Renal Failure & Severe Traumatic Brain Injury (“TBI”) with an estimated 216,000 patients in the US and the five other major markets with a $2.4 billion addressable market.
In addition to its portfolio of prodrugs, the Company is developing a portfolio of CBD analogue or synthetic derivative drugs for the treatment of bone disease or disorders:

KAL436 and KAL439, two compounds Kalytera is investigating to assess their potential ability to improve bone fracture healing. KAL436 and KAL439 are both synthetic derivative compounds of CBD that have been structurally modified to enhance solubility in water to improve potency.
In the U.S., bone fractures account for an estimated 10.2 million visits to hospitals and physician offices. Worldwide, more than 50 million fractures occur every year. Osteoporosis is the most common cause of fractures and the prevalence of it and low bone mass is expected to increase in coming years due primarily to the aging of the population.

KAL671, a unique synthetic fatty acid amide and an endocannabinoid-like molecule that may restore bone in persons suffering from osteoporosis, the most common bone disease. The global osteoporosis drugs market was valued at $8.4 billion in 2013 and is projected to reach $8.9 billion by 2020.
The Company anticipates receiving a decision from the IIA on its grant application in the third quarter of this year. The grant, if approved, will be non-dilutive to shareholders in the form of a conditional, non-recourse loan to be paid back from future royalties.

Commenting on its recent IIA grant application, Dr. Andrew L. Salzman, CEO of Kalytera, said, “Kalytera is developing an entirely new generation of CBD-derived medicines -- for FDA and EMEA pathways to commercialization -- offering increased efficacy and far less side effects (improved safety profile) to treat serious and chronic disease. Our science is viewed favorably by the biotechnology industry and is a strong candidate for grants such as those offered by the IIA.

“We have a world-class management team, and Boards of Directors and Advisors, composed of cannabis biotech industry leaders in Israel and the US enabling Kalytera to capitalize on opportunities worldwide to bring our proprietary pipeline of drugs to clinical stage and commercialization,” he added. “Concurrently with our research on the prodrugs and synthetic compounds, we are advancing our clinical research on CBD to treat GvHD, whose data from a recent Phase 2a study announced February 22, were encouraging.”

About Kalytera
Kalytera (TSXV:KALY) is a clinical-stage pharmaceutical company pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and growing intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs -- with an initial focus on Graft versus Host Disease (“GvHD”).

Kalytera is also developing a new class of proprietary cannabidiol (“CBD”) therapeutics. CBD is a remarkable compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with CBD, including its poor oral bioavailability which greatly limits the efficacy of medical marijuana edible products that contain a high level of CBD.

Kalytera is developing innovative CBD formulations and prodrugs intended for commercialization as FDA and EMEA-approved prescription medications in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera has filed composition of matter and method of use patents covering its novel inventions to reinforce its barriers to entry.

[sunny3999]

4 Top Stocks in the Growing Medical Marijuana Industry

http://www.huffingtonpost.com/entry/4-top-stocks-in-the-grow…
04/19/2017 05:47 pm ET

Investors have watched in awe as a large number marijuana stocks have made triple digit gains this past year. Public opinion on cannabis has moved more toward acceptance as people become more knowledgeable. In fact, a 2016 Gallup Poll showed 60% of Americans are for legalizing marijuana, which is up from 12% in 1969.

Increased public support and commercialization of the industry have made cannabis a growing industry. According to a recent Business Insider article, the North American marijuana market posted $6.7 billion in revenue in 2016, up 30% from the year before, based on a new report from Arcview Market Research, a leading publisher of cannabis market research.

Instead of gambling on which marijuana stock will move the most, many investors choose to focus on Medical Marijuana Companies, especially those focusing their research on cannabinoids (CBD), which are the active chemical components of the cannabis plant. Opposed to tetrahydrocannabinol (THC), which creates the pleasant psychoactive “high” that cannabis users are familiar with, CBD offers numerous therapeutic properties, such as anti-inflammatory, anti-anxiety, anti-schizophrenic, and anti-epileptic. So which companies will prosper and which shocks should you buy? Here are four companies in the Cannabis Pharma sector that have a tremendous amount of potential.

1. GW Pharmaceuticals

First on every list of cannabis-based drug developers is GW Pharmaceuticals (NASDAQ: GWPH). The company’s $3 billion market cap makes it the largest in the industry, even though it’s currently losing money. Keep in mind many biotech companies with drugs in various stages of the FDA approval process are also losing money, since they are pouring their cash into research and development. Epidiolex is GW Parmaceuticals experimental drug that has promising results for two rare forms of childhood-onset epilepsy in FDA phase 3 trials. In two trials for both Epidiolex, which is derived from a marijuana component called cannabidiol, or CBD, helped significantly reduce the number of monthly seizures suffered by patients with Lennox-Gastaut syndrome (LGS)—a rare disease that often strikes during childhood and usually causes debilitating epileptic episodes. It afflicts about 30,000 children and adults in the U.S., according to the LGS Foundation.

On March 27, 2017, GW Pharmaceuticals announced its Epidiolex had been granted Orphan Drug Designation by the European Medicines Agency for the treatment of Lennox-Gastaut Syndrome (LGS), a treatment-resistant and debilitating childhood-onset epilepsy. Epidiolex could, potentially, be a $1 billion drug, if it is approved by the FDA.

2. Kalytera Therapeutics, Inc.

Kalytera Therapeutics, Inc. (CVE: KALY) (OTC: QUEZF) is a clinical-stage pharmaceutical company pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs, with an initial focus on Graft versus Host Disease (“GvHD”). Kalytera is also developing a new class of proprietary cannabidiol (“CBD”) therapeutics. CBD is a remarkable compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with natural CBD, including its poor oral bioavailability. Kalytera is developing innovative CBD formulations and prodrugs in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera intends to file composition of matter and method of use patents covering its novel inventions, with the goal of limiting future competition.


Based in Beverly, Massachusetts, Kalytera has licensed a patent from the Hebrew University on CBD derivatives and will finance drug development based on the patent. Dr. Raphael Mechoulam, Ph.D., is the Co-Chair of the Scientific Advisory Board for Kalytera. He is also a pioneer in the field of cannabis research, having been the first scientist to complete total syntheses of THC and CBD. Dr. Mechoulam also serves as Professor of Medicinal Chemistry at the Hebrew University of Jerusalem in Israel.

Kalytera Chief Executive Officer Dr. Andrewn Salzman founded and built Inotek Pharmaceuticals, a 140-person biotech company that raised $92M in venture capital and concluded a $600M license with Genentech. As CEO of Inotek, Dr. Salzman brought numerous new chemical entities from conception to clinical stage testing, including a treatment for glaucoma that demonstrated clinical proof of concept in late Phase 2 clinical trials. Dr. Salzman has been funded by the U.S. National Institutes of Health, authoring 75 federal grants and receiving $164 million in federal grant and contract funding, $129 million in venture capital investment, and $27 million in strategic licensing and research support. He received an undergraduate degree from Yale College, a degree in medicine from Harvard Medical School, and completed a pediatric internship and residency at Columbia University Medical Center.

3. Corbus Pharmaceuticals

Corbus Pharmaceuticals (NASDAQ: CRBP) is developing anabasum, which is a synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation, and fibrotic processes. Anabasum was granted Orphan Drug Designation and Fast Track status by the FDA for the treatment of systemic sclerosis in 2015 and Orphan Drug Designation by the EMA in January 2017. Corbus recently completed a Phase 2 study for anabasum, which was supported by a $5 million award from Cystic Fibrosis Foundation Therapeutics, a nonprofit drug discovery and development affiliate of the CF Foundation.

Corbus has reported positive mid-stage results in systemic sclerosis and cystic fibrosis, however, anabasum is their sole drug. On April 5, 2017, Corbus Pharmaceuticals announced plans to commence a single Phase 3 study of anabasum for treatment of Systemic Sclerosis following guidance received from their successful end-of-Phase 2 Meeting with the FDA.

4. Zynerba Pharmaceuticals

Zybnerba Pharmaceuticals (NASDAQ: ZYNE) also depends on cannabinoid therapies as the foundation for ZYN001 and ZYN002, the two drugs it currently has in development. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.

ZYN001 could potentially treat fibromyalgia and peripheral neuropathic pain, as well as chronic cancer, chronic pain, and gastrointestinal disorders. ZYN002 is a cannabidiol-based gel that is absorbed through the skin and aimed at treating adult epilepsy, osteoarthritis, and Fragile X syndrome. The STAR 1 epilepsy study and STOP osteoarthritis study are expected to yield mid-stage, top-line results by July or August, while the FAB-C Fragile X trial should have mid-stage data by the end of the first half of 2017.

[sunny3999]

Wenn 5 Mio $ Forschungsgeld im 3Q erteilt wird, sollte Kalytera $1 Wert sein mit dem 25 Mrd Potential !

Infos from Stockhouse:
If the $ 5 Mio apply from IIA Grant will be approved (3Q 17), Healthcare industry will recognizes this potential of more than $25 bn

Kalytera should have no issue to reach $1 by end of 2017 and the financing will be much easier!

K-1012, indicated for Acute Respiratory Distress Syndrome (“ARDS”), with an estimated 280,000 patients just in the US and a $700 million addressable market.

K-1022, indicated for Ulcerative Colitis (also known as Irritable Bowel Syndrome, or “IBS”), with an estimated 800,000 US patients and a $10 billion addressable market.

K-1032, indicated for Acne Vulgaris, with an estimated 45 million patients in the US and the five other major markets with a $4 billion addressable market.

K-1052, being studied as an Inducible Nitric Oxide Synthase Inhibitor, indicated for Sepsis Associated Renal Failure & Severe Traumatic Brain Injury (“TBI”) with an estimated 216,000 patients in the US and the five other major markets with a $2.4 billion addressable market.
In addition to its portfolio of prodrugs, the Company is developing a portfolio of CBD analogue or synthetic derivative drugs for the treatment of bone disease or disorders:

KAL436 and KAL439, two compounds Kalytera is investigating to assess their potential ability to improve bone fracture healing. KAL436 and KAL439 are both synthetic derivative compounds of CBD that have been structurally modified to enhance solubility in water to improve potency.
In the U.S., bone fractures account for an estimated 10.2 million visits to hospitals and physician offices. Worldwide, more than 50 million fractures occur every year. Osteoporosis is the most common cause of fractures and the prevalence of it and low bone mass is expected to increase in coming years due primarily to the aging of the population.

KAL671, a unique synthetic fatty acid amide and an endocannabinoid-like molecule that may restore bone in persons suffering from osteoporosis, the most common bone disease. The global osteoporosis drugs market was valued at $8.4 billion in 2013 and is projected to reach $8.9 billion by 2020.

Monteviale wrote: Its a start... please check out link.

Kalytera Applies for $5 Million R&D Grant from IIA: https://globenewswire.com/news-release/2017/04/17/961274/0/e…

Read more at http://www.stockhouse.com/companies/bullboard?symbol=quezf&postid=26141366#m4cjJbytQRUqH4Ep.99

[Scorpio1921]

Antwort auf Beitrag Nr.: 54.766.234 von sunny3999 am 20.04.17 13:09:16

wieso wird dieses Papier gelöscht?

sunny3999 was da los?

[sunny3999]

Antwort auf Beitrag Nr.: 54.809.578 von Scorpio1921 am 26.04.17 13:38:47

Wenn ich das wüßte was hier gespielt wird ? Aber ich bleibe erst mal investiert....

Zitat von Scorpio1921: sunny3999 was da los?

[manffreddoo]

hi,
wieso ist der Kurs in den letzten beiden Monaten so fulminant von0,05 auf im Hoch über 0,20 $ gestiegen..............
Gab es News vom Unternehmen oder ist der Anstieg lediglich der Hausse in der Cannabisindustrie geschuldet?
M.

[Nico1977]

alytera Therapeutics receives second U.S. patent

2018-05-02 10:20 ET - News Release


Mr. Robert Farrell reports

KALYTERA ANNOUNCES ISSUANCE OF SECOND PATENT COVERING THE USE OF CBD IN GRAFT VERSUS HOST DISEASE

The U.S. Patent and Trademark Office (USPTO) has issued to Kalytera Therapeutics Inc. U.S. patent No. 9,956,182 with claims covering the use of cannabidiol (CBD) for the prevention and treatment of acute and chronic forms of graft-versus-host disease (GVHD). Kalytera has exclusive worldwide rights to this issued patent through an exclusive licence agreement with MOR Research Applications Ltd. of Israel.

GVHD is a multisystem disorder that is a life-threatening complication commonly occurring after bone marrow transplant procedures. GVHD occurs when the transplanted donor cells attack the patient's organs, including the skin, gastrointestinal tract, liver, lungs and eyes. GVHD is associated with acute and chronic illness, infections, disability, reduced quality of life and death.

In November, 2017, Kalytera announced that it had received notice from the USPTO that the application for this patent would be allowed. The issuance of this patent by the USPTO is the final step in the patent application process and provides patent coverage to Kalytera for the use of CBD in the prevention and treatment of acute and chronic forms of GVHD through May, 2034, under the exclusive licence agreement with Mor.

This is the second patent covering the use of CBD in GVHD that Kalytera has received in the past three weeks. On April 19, 2018, Kalytera announced that the USPTO had issued U.S. patent No. 9,889,100 B2 with claims covering the use of CBD for the treatment of severe and refractory GVHD.

"We are delighted by the issuance of this second patent for CBD in the treatment and prevention of GVHD," said Robert Farrell, president and chief executive officer of Kalytera. "We now have very strong intellectual property protection that will provide us with market exclusivity for the use of CBD in GVHD through early 2034."

Mr. Farrell went on to state: "Our program for prevention of GVHD is in phase 2 clinical testing, and, later this year, we will begin a phase 3 pivotal registration study in the treatment of GVHD. With our GVHD program advancing into the final phases of clinical testing, we will now begin seeking regional partners for commercialization of this product outside of North America. Such partnering agreements can provide non-dilutive sources of funding through licensing, milestone and royalty revenue opportunities."

The commercial opportunity for Kalytera's CBD product in the treatment and prevention of GVHD is large. According to the January, 2018, market forecast report by DelveInsight Perspective, the potential size of the market for a successful product in the seven major jurisdictions (the United States, Germany, France, Italy, Spain, the United Kingdom and Japan) is estimated to be more than $408-million (U.S.) in 2018 and could grow to approximately $1.3-billion (U.S.) by 2027.

Kalytera acquired its program in the prevention and treatment of GVHD in February, 2017, through the acquisition of Talent Biotechs Ltd. of Israel. Under its agreement with the former Talent Biotechs shareholders, Kalytera is obligated to make additional contingent payments to the former Talent Biotechs shareholders upon the achievement of certain milestones, including upon the issuance of patents by the USPTO. Upon the earlier issuance of U.S. patent No. 9,889,100 B2 by the USPTO, Kalytera became obligated to make a payment to the former Talent Biotechs shareholders of 2,883,535 common shares and a cash payment of $2-million (U.S.). With the issuance of U.S. patent No. 9,956,182 by the USPTO, Kalytera is now obligated to make an additional cash payment to the former Talent Biotechs shareholders of $2-million (U.S.).

http://www.stockwatch.com/News/Item.aspx?bid=Z-C:KALY-260267…

[Nico1977]

[watchi]

Alter Falter... da kann aber noch was gehen die Tage!

[Nico1977]

VANCOUVER, Sept. 13, 2018 /CNW/ - The following issues have been halted by IIROC:

Company: KALYTERA THERAPEUTICS INC

TSX-Venture Symbol: KALY; KALY.WT

Reason: Pending Company Contact

Halt Time (ET): 13:04

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

[watchi]

Ging denen wohl zu steil.
Aber gut, erregt Aufmerksamkeit.

[watchi]

Nachher geht's nochmal für die letzten 15min weiter. Man darf gespannt sein.

[Nico1977]

Heute war erst der Anfang einer guten Story. Morgen geht es lustig weiter!

[watchi]

Vermute ich auch, das war ja erst der erste Tag!
Das nach dem Halt einige geschmissen haben, war zu erwarten. Aber daß eine Aktie am ersten Tag raketenartig abgeht, nur um am zweiten wieder dahin zu gehen, wo sie herkam - das hab ich noch nie erlebt. Insofern bin ich da auch recht optimistisch für die nächsten Handelstage.

[Nico1977]

aktuell schaut es gut in Can aus.
227k im Bid für 0.13

[Nico1977]

Antwort auf Beitrag Nr.: 58.701.201 von Nico1977 am 14.09.18 15:03:33

Bid steigt. 617k bei 0,135

[watchi]

Sieht doch gut aus heute. Schock verdaut, weiter geht's!

[backonplastic]

Über 1 Mio im Bid ! Okay 👌

[backonplastic]

Hat sich nach diesem Anstieg und für einen Freitag gut gehalten. Das Bid war dick gestern ... bin auf nächste Woche gespannt. Allen ein schönes Wochenende

[backonplastic]

Schon etwas älter...

https://smallcappower.com/analyst-articles/kalytera-therapeu…

Und hier eine Übersicht der aktuell laufenden Forschung ...

https://kalytera.co/programs/

Bei der aktuellen Bewertung sowie dem Zukunftspotential muss man bei zugrundeliegender Bewertung wohl nicht viel sagen. Der Kursanstieg letzte Woche war wohl nur der Anfang. Eine faire Bewertung dürfte um ein Vielfaches höher liegen!

Ich bin gespannt auf nächste Woche und wann der Markt diese Perle entdeckt.

[backonplastic]

Übrigens kann hier jeder Zeit was neues bezüglich einer Zulassung seitens der FDA kommen - so viele Shares wie letzte Woche werden nicht umsonst gehandelt .... scheint was im Busch zu sein .... bin gespannt.

Übrigens - spricht für die Firma, das bei so einem Anstieg mal die Bremse in Form von einem Halt gezogen wird. Wirkt auf mich irgendwie seriös 😎

Der Run hier wird kommen - die großen Schichten in günstige Papiere um , wenn Ihre Player heißgelaufen sind ...

[beppels]

Antwort auf Beitrag Nr.: 58.711.207 von backonplastic am 16.09.18 12:40:17

Gute Woche voraus!

Hi backonplastic,

Schön das du auch bei kalytera im Boot bist! Das sehe ich als gutes Omen an, wir beide haben im Januar zusammen viel geld bei juju.a verdient! Die habe ich letzte Woche mit schönem Gewinn getauscht in kalytera. Vom Chart her sehen die ähnlich aus wie juju vor einer Woche und die haben sich dann verdreifacht.
Mit dem Sprung über die 10 ca cents ist alles bereit für den schnellen verdoppler!

[backonplastic]

Hey beppels, danke für die Blumen. 😎 Kalytera ist noch ziemlich am Anfang , wie viele andere die Cannabis als Medikament erforschen - ABER wir befinden uns bereits in Phase 2 - Meldung zu Phase 3 kann jederzeit kommen. Mann muss hier auch zu synthetisch hergestellten Medikamenten unterscheiden , da das Nebenwirkungsprofil zum Beispiel viel geringer einzuschätzen ist. Sprich das läuft alles viel schneller. Zugelassene Medikamente mit Cannabinoid haben bisher noch nicht viele Unternehmen vorzuweisen - daher gilt hier nicht das Prinzip die letzen werden die ersten sein. 😉 die Krankheiten zu denen Kalytera forscht sind vom zu erwartenden Umsatz auch nicht gerade gering, sofern hier was zugelassen wird rappelt es im Karton - man sollte sich jetzt auch nicht von dem Kurszuwachs der letzten Tage abschrecken lassen , an der Börse wird die Zukunft gehandelt Und anhand der aktuellen Marktkapitalisierung ist noch reichlich Luft nach oben - in Kanada erwarten viele News nächste Woche - Kalytera hat in Zusammenhang mit dem Halt jedoch mitgeteilt , dass es keinen Grund für den Anstieg gibt /// okay , das wäre auch nicht schlimm, dann hätte der Markt einfach nur das Potential erkannt, in Kombi mit der Cannabishausse aktuell ... wäre das nicht schlecht. Bin auf morgen gespannt ... hoffentlich gehts weiter oder es hält auf aktuellen Niveau ... so niedrig bewertete Stocks im Sektor findet man kaum mehr . Greetz BaCkOn ✌️

[backonplastic]

Hat jemand mal ein link zur vorbörse bei den Holzfällern ? DAnke

[Diversifikation]

Antwort auf Beitrag Nr.: 58.718.029 von backonplastic am 17.09.18 13:31:23

Kalytera ist sicher mit Hinsicht auf die Produktpipeline als auch auf die Investoren ein interessanter Wert. Die laufende Studie, die ja auf eine mögliche FDA Zulassung 2017 von der notwendigen Ethikkommission zugelassen wurde, läuft seit dem letzten Jahr an zwei Kliniken in Israel und hier sind entsprechende Ergebnisse in einem überschaubaren Zeitraum zu erwarten. Akute Graft versus Hiost Reaktionen betreffen immerhin 30-60% der Stammzelltransplantierten, chronisch ca. 70%.

Ein weiterer Aspekt ist hier einer der Investoren, nämlich MMCAP international inc., der im Mai 7,94% oder etwas mehr als 15 Mio. Aktien erworben hat (Sedar- siehe unten). Dieser den meisten unbekannte Investor ist tatsächlich einer der Hauptakteure in der Finanzierung von Cannabis-Firmen und war/ist maßgeblich an Unternehmen wie Aphria, Aurora oder Cannabis Wheaton beteiligt bzw. hat diese finanziert. Wenn sich also jemand mit sinnvollen Investments in diesem Bereich auskennt, dann vermutlich dieses Unternehmen.


Quelle Sedar: As at the end of May 2018, MM Asset, on behalf of MMCAP, exercised control and direction over 15,191,700 common share purchase warrants (each warrant is exercisable for one Share at a price of $0.13 on or before December 20, 2019) representing approximately 7.94% of the Issuer’s 176,185,221 issued and outstanding Shares as reported by the Issuer in its Management’s Discussion and Analysis of Financial Condition and Results of Operations as of May 30, 2018, calculated on a partially diluted basis.

[Diversifikation]

Antwort auf Beitrag Nr.: 58.721.986 von Diversifikation am 17.09.18 21:16:43

Zumindest wirtschaftlich deutlich interessanter als die Medikamente in der doch seltenen GvH-Reaktion finde ich jedoch diesen Teil, die Schmerzmedikation:

addition to our lead program in GVHD, we have also initiated a preclinical program to develop a novel, proprietary cannabinoid compound for the treatment of acute and chronic pain. Our compound consists of a next-generation cannabinoid compound conjugated with naproxen, a generic, non-steroidal, anti-inflammatory drug that is already approved for treatment of pain. This cannabinoid/naproxen conjugate has potential to become a next generation pain medication, without the risks of addiction or respiratory suppression that exist with opioid analgesics. We have found a way to make this compound water soluble, which will allow for treatment of acute pain in in-patient settings, such as childbirth, short surgical procedures, and post-operative pain care. We have applied for patent coverage in the U.S, Europe and other jurisdictions for this novel cannabinoid compound for the treatment of pain.


Das ist nämlich ein wahrer Blockbuster-Markt, der in Deutschland allein bei den freiverkäuflichen Medikamenten bei annähernd 600 Mio. € und weltweit bei vielen Mrd. € liegt. Wer da ein gutes Präparat zugelassen bekommt...

[watchi]

2018-09-20 08:06 ET - News Release
Kalytera expands CBD study sites

https://www.stockwatch.com/News/Item.aspx?bid=Z-C:KALY-26612…

[watchi]

Obacht... in CAN kommt wieder Musik rein.

[Diversifikation]

Und die Musik spielt heute erstmal weiter. Anziehendes Volumen und ein Aufschlag von bis zu 25% auf 0.16-0.17, könnte oder sollte den Handel in D auch etwas beleben.

[Diversifikation]

Antwort auf Beitrag Nr.: 58.782.830 von Diversifikation am 24.09.18 15:57:35

Über 9 Mio. Aktien in Übersee mit einem sich über den Tag stabilisierenden Aufschlag und über 75.000 Aktien in D - es kommt langsam aber sicher etwas Bewegung in den Wert.

[beppels]

das scheint heute endlich der Ausbruch über die 14-15 cents zu werden, dann sind 20 cents der nächste halt!😄

[watchi]

Kalytera Announces Grant of Stock Options to Directors and Employees

https://globenewswire.com/news-release/2018/09/25/1575367/0/…

[soulist]

Kalytera Therapeutics has a huge upside, says Echelon
AUGUST 20, 2019 BY NICK WADDELL

"Echelon Wealth Partners analyst Douglas Loe calls the new update from Kalytera Therapeutics (Kalytera Therapeutics Stock Quote, Chart, News TSXV:KLY) “highly positive”.

Saying the cannabinoid-focused drug developer is likely to proceed to Phase III trials for its CBD-based drug formulation. In a Healthcare & Biotechnology update to clients on Monday, Loe maintained his “Speculative Buy” rating and $0.30 price target, which at the time of publication represented a 567-per-cent return...."

https://www.cantechletter.com/2019/08/biotech-penny-stock-ka…

[soulist]

Antwort auf Beitrag Nr.: 61.307.131 von soulist am 21.08.19 11:47:28

Summary
Kalytera Therapeutics recently released Phase 2 clinical data with extremely positive results for its CBD product in the prevention of acute graft versus host disease.

More than half of patients receiving bone marrow transplants from matched unrelated donors are susceptible to GVHD; only one of the 24 patients under the Phase 2 study developed it.

Kalytera will be initiating a Phase 3 study, with results expected in a year.

Kalytera makes an extremely good partner and advocate for GW Pharma as its CBD medical research expands beyond epilepsy.

Echelon Wealth Partners has a $0.30 target on Kalytera.

https://seekingalpha.com/article/4287950-kalytera-set-become…

[Win_the_Game]

Hier wird die nächste Party losgehen🤑

[soulist]

Antwort auf Beitrag Nr.: 61.353.463 von Win_the_Game am 27.08.19 18:45:39

Zitat von Win_the_Game: Hier wird die nächste Party losgehen🤑

Absolut - schlanke 18Mio$ Marktkapitalisierung und spektakuläre Phase 2 Resultate

https://timesofcbd.com/kalytera-therapeutics-reveals-interim…

[soulist]

Antwort auf Beitrag Nr.: 61.354.261 von soulist am 27.08.19 20:17:40

First there was a big crowd, about 5 of us...🙂

The meeting that was lead by Rob Farrell, which I find really calm and really knowledgeable of the product, he went on describing pretty precise on detail, and this was very good to have an understanding of the GVHD product.
He also talk about phase 2.
We should all be done with phase 2 this year (Pretty soon)… with better results.
And they probably won’t need to test the high dosage(300 mg)
Because they already know that higher level is not good at one point, so we should be good to go after the dosage of 150 mg. they know this from GW pharma studying.
He also talk about the process the small pharma go thru.
He said that Big pharma wait for phase 2 to be completed before they get involved.
The way he said it is sound like they already have this partner line up… of course you can’t say it would be illegal, I’ve got a personal feeling that GW Pharma is highly interested in this company.
Once a partner join they would take care of all phase 3 Financing, so no more Dilution to get phase 3 done.
So now we have to wait for phase 2 to be done and we should know about a partner right after. Then no more fees.
He also talk about bringing revenue thru Royalties and Licences (As soon as phase 2 is done)… which bring $ and you don’t have to do nothing.
Oregon Hemp farm.
He brought the subject of the last acquisition, in short this could be brining over 18 Millions as a really conservative number next year…. Which would mean profit of around 5-10 Millions next year.
He mention that Eclipse would already buy all of there production to produce hemp Drink.
I did a search on eclipse and they are a very well establish and need a lot of CBD
And this farm got room to grow if required.
And finally we briefly talk about Kal-1816, which is the CBD molecule modified by kaly and patented, as we all know GVHD is about 600 Millions a years, and Opiod is over 20 Billions a year in the state alone… of course we are just starting with Kal-1816…
The way we spoke I believe is open to a partnership and a buyout but not know, since the price is so ridiculously undervalued…but in 4-5 Years Kal-1816 will be ready… unless they speed it up.
He also talk about getting a Toronto base business to promote Kaly.
I've also mention that most of the individual I've talk to we're against the RS because of the Shorter. So once we get a partner and phase 2 done we could have to vote... he said that it need to be at 5$ to get on the nasdaq..
In short this is it.
I’ve got a great feeling after talking with him.
Now let’s have phase 2 done and wait for the good news that will follow …

Read more at https://stockhouse.com/.../kalytera-therapeutics-inc...

[dabertomalso]

Wieso geht es mit der Aktie nur bergab? Man befindet sich doch in einer sehr weiten Phase der Produktentwicklung und hat dann Monopolstellung......

[Win_the_Game]

Antwort auf Beitrag Nr.: 61.736.113 von dabertomalso am 21.10.19 16:51:26

Weil die noch nicht die komplette Finanzierung durch haben.....Zum Jahresende geht das Geld aus.

[dabertomalso]

Ja aber die dürften doch wohl in diesem Entwicklungsstadium einen passenden PharmaPartner finden, zumal es kein vergleichbares Produkt auf dem Markt gibt....

[Win_the_Game]

Ob es ein vergleichbares Produkt gibt das weiß ich nicht. Das müsste man recherchieren. Aber solange keiner den Laden finanzieren will, solange wird hier nichts passieren. Hört sich alles gut an, aber keine Finanzpartner vorhanden.....woran das liegt...keine Ahnung. Ich bin und war hier nicht investiert.

[Ruqqq]

Weiß jemand etwas über den Anstieg seit 2 Tagen?
Mögliche Arbeit an Covid-Vaccine oder Ähnliches?

[Anders-And]

https://claritaspharma.com/claritas-formerly-kalytera-therap…

[Anders-And]

https://ceo.ca/@nasdaq/claritas-formerly-kalytera-therapeuti…

[Anders-And]

Übersetzt mit deepl.com

Kalytera Therapeutics, Beetlebund Lizenzvereinbarung

2021-03-03 20:37 ET - Eigentumsvereinbarung


Die TSX Venture Exchange hat die Dokumentation einer Lizenzvereinbarung vom 30. März 2018 zwischen dem Unternehmen und Beetlebung Pharma Ltd. zur Einreichung akzeptiert. Gemäß den Bedingungen der Vereinbarung hat das Unternehmen mit dem Verkäufer eine weltweite Exklusivlizenz in Bezug auf seinen cannabinoidbasierten Wirkstoff erhalten, mit dem der Verkäufer ein Entwicklungsprogramm zur Behandlung von akuten und chronischen Schmerzen aufgebaut hat. Als Gesamtgegenleistung hat das Unternehmen beschlossen, dem Verkäufer eine Reihe von Meilensteinzahlungen zu gewähren, die wie folgt beschrieben werden:

Eine Gesamtsumme von Barzahlungen in Höhe von ca. 4.325.000 US-Dollar wird bei Erreichen bestimmter Meilensteine gemäß den Bedingungen der Vereinbarung gezahlt, vorbehaltlich zusätzlicher Unterlizenzierungsgebühren;
Eine Erfolgsprämie wird bei Erhalt der Zulassung durch die U.S. Food and Drug Administration (FDA) fällig, wobei die Gegenleistung an den Verkäufer durch die Ausgabe von insgesamt 6,5 Millionen Stammaktien und eine Barzahlung in Höhe von:
Der Betrag, um den der Schlusskurs der Aktien des Unternehmens an der Börse am Tag der Bekanntgabe der FDA-Zulassung multipliziert mit 5 Prozent der zu diesem Zeitpunkt ausgegebenen und ausstehenden Aktien des Unternehmens den Wert der Success Fee-Aktien übersteigt.
Gemäß den Bedingungen der Vereinbarung wird der Verkäufer auch berechtigt sein, eine 5-Prozent-Lizenzgebühr aus dem Nettoumsatz des Cannabinoid-basierten Präparats in jedem Land zu erhalten, in dem das entsprechende Patent geschützt ist. Darüber hinaus ist das Unternehmen verpflichtet, eine Barzahlung von 150.000 US-Dollar zu leisten, sobald das erste Patent in jedem der folgenden Länder erteilt wird:

Die Vereinigten Staaten;
Japan;
Jedes der fünf unten genannten europäischen Hauptländer:
Deutschland;
Frankreich;
Das Vereinigte Königreich;
Spanien;
Italien.
Insider/Pro-Gruppen-Beteiligung: keine

Für weitere Informationen verweisen wir auf die Pressemitteilungen des Unternehmens vom 13. April 2018 und 24. Februar 2021.

© 2021 Canjex Publishing Ltd. Alle Rechte vorbehalten.

https://www.stockwatch.com/News/Item?C:KLY&bid=Z-C:KLY-30423…

[Competizione67]

Antwort auf Beitrag Nr.: 67.300.056 von Anders-And am 04.03.21 10:34:35

https://mobile.twitter.com/KushMansPicks/status/136710848038…

Des Weiteren geht es auch um eine Behandlung gegen Covid19 "to Accelerate Development of R-107 for Treatment of Vaccine-Resistant COVID-19, Influenza, and Other Viral Infections "

Gruß

[Anders-And]

https://pro.ceo.ca/@nasdaq/claritas-formerly-kalytera-therap…

[Competizione67]

Antwort auf Beitrag Nr.: 67.305.294 von Anders-And am 04.03.21 14:35:22

sag ich doch

Gruß

[Anders-And]

https://ceo.ca/@nasdaq/claritas-formerly-kalytera-therapeuti…

[Anders-And]

https://ceo.ca/@nasdaq/claritas-announces-formation-of-nitri…

[Anders-And]

https://claritaspharma.com/claritas-announces-addition-of-pe…

[Anders-And]

https://ceo.ca/@nasdaq/claritas-announces-completion-of-cani…